Annovis Bio, Inc.
Annovis Bio, Inc. (ANVS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ANVS · as of Jun 9, 2026
Key Statistics
Explore Annovis Bio, Inc. Data
anvs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 75.0%
The ANVS analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $25.67, representing +1334.08% upside from the current price of $1.79.
Competitors & Peers
anvs competitorsANVS
ATNM
BCAB
BTAI
CELU
ELUTStock Performance
Full HistoryAbout Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successf…
what is annovis bio, inc. · anvs stock overview · annovis bio, inc. company profile · who is annovis bio, inc. ceo · anvs NYSE · annovis bio, inc. headquarters · annovis bio, inc. business segments
About Stock Overview & Key Data
Annovis Bio, Inc. (ANVS) is a Healthcare company in the Biotechnology industry, listed on NYSE since Jan 29, 2020. As of the latest trading session, ANVS stock price is $1.79, with a market capitalization of $35.2M. The stock has returned -41.50% over the past 12 months and -48.27% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Annovis Bio, Inc. stock is Buy, with an average 12-month price target of $25.67. In fiscal year 2025, Annovis Bio, Inc. reported revenue of — and net income of -$28.9M. For detailed data — including Annovis Bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Annovis Bio, Inc. (ANVS) stock price is $1.79. The stock is traded on NYSE under the ticker symbol ANVS. The 52-week range is $1.54 – $5.50.